Adjuvants, Immunologic ; therapeutic use ; Animals ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Phytotherapy ; Systemic Inflammatory Response Syndrome ; complications ; drug therapy

Imiquimod (R-837) and Resiquimod (R-838), two novel small-molecular-weight immune response modifiers, have similar structure. They have anti-virus and anti-tumor activities and can be used as B lymphocyte activators and adjuvants. They are widely used in dermatology to treat virus dermatoses and cutaneous benign or malignant tumors.
Adjuvants, Immunologic ; therapeutic use ; Aminoquinolines ; therapeutic use ; Antineoplastic Agents ; therapeutic use ; Condylomata Acuminata ; drug therapy ; Humans ; Imidazoles ; therapeutic use ; Skin Neoplasms ; drug therapy

Adjuvants, Immunologic ; therapeutic use ; Antiviral Agents ; therapeutic use ; China ; Drug Therapy, Combination ; Hepatitis B, Chronic ; therapy ; Humans ; Interferon-alpha ; therapeutic use ; Lamivudine ; therapeutic use

Adjuvants, Immunologic ; therapeutic use ; Adrenal Cortex Hormones ; therapeutic use ; Antibodies, Viral ; therapeutic use ; Controlled Clinical Trials as Topic ; Forecasting ; Humans ; Research ; trends ; Research Design ; Severe Acute Respiratory Syndrome ; therapy

Changes in sexual behavior may constitute an important contribution to relative increase in genital herpes. Many research results suggest that HSV-2 plays a big part in the transmission of HIV infection. There is an urgent need to identify effective HSV-2 control measures in order to reduce HIV incidence. The detection of HSV-2-specific antibodies in serum is especially useful and reliable. During the past 2 decades, selective and specific inhibitors of replication have been developed. Such agents as acyclovir, valaciclovir and famciclovir, have reduced the time of healing and the possibility of virus excretion. Efforts have been made in different directions including the exploration of new targets for antiviral chemotherapy, the use of immunomodulators and the development of specific vaccines.
Adjuvants, Immunologic ; therapeutic use ; Antiviral Agents ; therapeutic use ; China ; epidemiology ; Herpes Genitalis ; diagnosis ; epidemiology ; therapy ; Herpes Simplex Virus Vaccines ; therapeutic use ; Humans

The pathogenesis of diabetic nephropathy is influenced by multiple factors, among them, the pivotal action of inflammation on the development process of diabetic nephropathy has been proven with more and more evidences. In this article, the role of inflammation in the pathogenesis of diabetic nephropathy, the progress on researches of anti-inflammation and immune regulation, as well as the Chinese medicine therapy against diabetic nephropathy are introduced.
Adjuvants, Immunologic ; therapeutic use ; Animals ; Anti-Inflammatory Agents ; therapeutic use ; Diabetic Nephropathies ; drug therapy ; etiology ; Drugs, Chinese Herbal ; therapeutic use ; Humans

Bladder cancer is one of the common malignant tumors in China, with 75% of bladder cancer being non-muscle invasion with a high recurrence rate after surgery. Intravesical therapy is an useful methods to either directly kill tumor cells by infusing cytotoxic drugs into the bladder or directly or indirectly induce local immune responses of the body through infusing immune agents, such as bacillus calmette guerin, and thus reduce the risk of tumor recurrence and progression. In 2019, the Urological Chinese Oncology Group issued the "Expert consensus on intravesical therapy on non-muscle invasive bladder cancer" . Recently, great progress in the clinical diagnosis and treatment of non-muscle invasive bladder cancer has been achieved domestically and abroad, including the risk assessment of non-muscle invasive bladder cancer, the therapeutic choice of intravesical drugs, the adverse reactions and treatment experience of intravesical therapy, and clinical research on new types of intravesical drugs. This consensus is made according to domestic and overseas evidence-based medicine in combination with current clinical practice and experience of intravesical therapy for non-muscle invasive bladder cancer in China. It is an update of the 2019 expert consensus, with the wish to provide a guidance for domestic clinical standardized intravesical therapy for non-muscle invasive bladder cancer.
Adjuvants, Immunologic/therapeutic use* ; Administration, Intravesical ; Consensus ; Humans ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/drug therapy* ; Urinary Bladder Neoplasms/drug therapy*

Adjuvants, Immunologic ; adverse effects ; therapeutic use ; Azathioprine ; adverse effects ; therapeutic use ; Cyclosporine ; adverse effects ; therapeutic use ; Glucocorticoids ; adverse effects ; therapeutic use ; Humans ; Mycophenolic Acid ; adverse effects ; analogs & derivatives ; therapeutic use ; Tacrolimus ; adverse effects ; therapeutic use

BACKGROUNDImmunostimulating agents made from bacterial extracts represent a class of medications that contains antigens derived from several bacterial strains and their potential ability to prevent bacterial infections results from the stimulation of the nonspecific component of the immune system. The present study investigated the effect of the oral immunostimulant Broncho-Vaxom, which includes material from eight different species of bacteria that are frequently present in the lower respiratory tract, on the frequency and severity of acute exacerbation in patients with chronic bronchitis accompanied by chronic obstructive pulmonary disease (COPD).

METHODSNinety patients with chronic bronchitis complicated with COPD were randomly divided into groups A and B. Forty-nine subjects in group A received oral capsules containing 7 mg Broncho-Vaxom, while 41 patients in group B received similar placebo capsules. Both groups took one capsule daily for the first 10 days of each month for 3 consecutive months. The frequency of acute exacerbation, symptom scores, and lung function were recorded for the following one year period.

RESULTSThere was a significant decrease in the incidence, duration, and severity of acute exacerbation, as well as a reduction in the course of antibiotics administered and in the dosage of bronchodilator and mucolytic agent in group A, as compared to group B (P < 0.05, respectively). Symptom scores for cough, sputum, dyspnea, as well as symptoms observed upon auscultation of the chest also improved significantly in group A as compared to group B (P < 0.05, respectively). The bacterial clearance rate in sputum cultures from patients who received no antibiotics for the first 3 months was also significantly higher in group A compared to group B (P < 0.01).

CONCLUSIONSOrally administered Broncho-Vaxom is associated with a decrease in the incidence of acute exacerbation and a decrease in the need for antibiotics and symptomatic relief medications in patients with chronic bronchitis accompanied by COPD. Broncho-Vaxom is also associated with a decrease in symptom scores. Without causing any apparent adverse effects, this drug may also help to eradicate pathogenic bacteria in the airways.

Adjuvants, Immunologic ; therapeutic use ; Aged ; Aged, 80 and over ; Bacteria ; Bronchitis ; complications ; Cell Extracts ; therapeutic use ; Chronic Disease ; Female ; Humans ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive ; physiopathology ; therapy

Adjuvants, Immunologic ; therapeutic use ; Adult ; Aged ; Female ; Humans ; Liver Cirrhosis ; therapy ; Male ; Middle Aged ; Peritonitis ; therapy ; Thymosin ; analogs & derivatives ; therapeutic use